Barclays initiated coverage of Kymera Therapeutics (KYMR) with an Overweight rating and $60 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics initiated with an Outperform at RBC Capital
- Kymera Therapeutics Announces New Chief Legal Officer
- Kymera Therapeutics appoints Adams as Chief Legal Officer, Corporate Secretary
- Kymera Therapeutics: Promising Clinical Developments and Strategic Positioning in STAT6 Landscape Justify Buy Rating
- Kymera Therapeutics’ Earnings Call: Optimism and Strategic Progress